CRLF2 overexpression results in reduced B cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome

Children with Down syndrome (DS) have a 10-fold increased risk of developing B cell acute lymphoblastic leukemia (B-ALL), and have poorer outcomes due to both increased relapse and treatment-related mortality [1, 2]. The spectrum of cytogenetic alterations is very different in DS compared to non-DS ALL. Approximately half of DS-ALL cases have cytokine receptor-like factor 2 rearrangements (CRLF2-R), compared to only 5-10% of non-DS ALL cases, with half of these also having Janus Kinase 2 (JAK2)-activating point mutations [3-8].

Source: Experimental Hematology - March 16, 2022 Category: Hematology Authors: Jacob J. Junco, Barry Zorman, Vincent U. Gant, Jaime Mu ñoz, H. Daniel Lacorazza, Pavel Sumazin, Karen R. Rabin Source Type: research